Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2010; 20(01): 13-19
DOI: 10.4103/0971-3026.59746
PET/CT

Forced diuresis and dual-phase 18F-fluorodeoxyglucose-PET/CT scan for restaging of urinary bladder cancers

S Harkirat
Department of Nuclear Medicine and PET/CT Facility, Army Hospital (R and R), New Delhi, India
,
SS Anand
Department of Nuclear Medicine and PET/CT Facility, Army Hospital (R and R), New Delhi, India
,
MJ Jacob
Department of Nuclear Medicine and PET/CT Facility, Army Hospital (R and R), New Delhi, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Context: The results of 18 F-fluorodeoxyglucose (FDG)-PET imaging carried out with the current standard techniques for assessment of urinary tract cancers have been reported to be less than satisfactory because of the urinary excretion of the tracer. Aims: To investigate the role of dual-phase FDG-PET/CT in the restaging of invasive cancers of the urinary bladder, with delayed imaging after forced diuresis and oral hydration as the scanning protocol. Settings and Design: FDG-PET has been considered to be of limited value for the detection of urinary tract cancers because of interference by the FDG excreted in urine. We investigated the efficacy of delayed FDG-PET/CT in the restaging of invasive bladder cancer, with imaging performed after intravenous (IV) administration of a potent diuretic and oral hydration. Materials and Methods: Twenty-nine patients with invasive cancer of the urinary bladder were included in this study. Patients were divided into two groups: Group I (22 patients) included cases with invasive bladder cancer who had not undergone cystectomy and group II (seven patients) included cases with invasive bladder cancer who had undergone cystectomy and urinary diversion procedure. All patients underwent FDG-PET/CT scan from the skull base to the mid-thighs 60 min after IV injection of 370 mega-Becquerel (MBq) of FDG. Additional delayed images were acquired 60-90 min after IV furosemide and oral hydration. PET/CT data were analyzed as PET and CT images studied separately as well as fused PET/CT images and the findings were recorded. The imaging findings were confirmed by cystoscopy, biopsy or follow-up PET/CT. Results: The technique was successful in achieving adequate washout of urinary FDG and overcame the problems posed by the excess FDG in the urinary tract. Hypermetabolic lesions could be easily detected by PET and precisely localized to the bladder wall, perivesical region and pelvic lymph nodes. PET/CT delayed images were able to demonstrate 16 intravesical lesions (in 13 patients), with excellent clarity. Lymph node metastases were detected in a total of six patients. Of these, in two patients, FDG-avid lymph nodes were evident only in the delayed images. The information provided by the postdiuretic delayed images changed the PET/CT interpretation in 14 patients of invasive bladder cancer: Recurrent bladder lesions were identified in 12 patients, pelvic lymph node metastasis (only) in one patient and bladder lesion as well as lymph node metastasis in one patient. Distant metastases were detected by PET/CT in two cases. CT scan was false-negative for early recurrence in the bladder wall for seven of 16 lesions. CT also showed two false-positive lesions. There were no false-positives with PET. Conclusions: Detection of recurrent disease in cases of invasive bladder cancer can be significantly improved by using FDG-PET/CT, with delayed imaging following forced diuresis and oral hydration. Composite PET/CT is superior to CT alone for the restaging of invasive bladder cancers.

Keywords

Bladder cancer - FDG-PET/CT - forced diuresis


Publication History

Article published online:
02 August 2021

© 2010. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Oehr P, Biersack HJ, Coleman RE (Eds). PET and PET-CT in oncology. first Ed. Heidelberg: Springer-Verlag; 2004. p. 1-364.
  • 2 Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93.
  • 3 Schöder H, Larson SM, Yeung HW. PET/CT in oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004;45:72S-81.
  • 4 Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in the evaluation of cancer: Additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200-9.
  • 5 Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET-CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 2004;22:4357-68.
  • 6 Freudenberg LS, Antoch G, Schütt P, Beyer T, Jentzen W, Müller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31:325-9.
  • 7 Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7.
  • 8 Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of 18 F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-803.
  • 9 Jadvar H, Parker JA. PET radiotracers. In: Clinical PET and PET/CT. first ed. London: Springer; 2005. p. 45-67.
  • 10 Kumar R, Zhuang H, Alavi A. PET in the management of urologic malignancies. Radiol Clin North Am 2004;42:1141-53.
  • 11 Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-92.
  • 12 Hain SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int 2003;92:159-64.
  • 13 Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control 2002;9:335-42.
  • 14 Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-20.
  • 15 Ahlström H, Malmström PU, Letocha H, Andersson J, Långström B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996;37:180-5.
  • 16 Cook GJR. Artifacts and normal variants in whole-body PET images. In: Valk PE, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission Tomography: Basic Science and Clinical Practice. London, U.K.: Springer-Verlag; 2003. p. 495-505.
  • 17 Leisure GP, Vesselle HJ, Faulhaber PF, O′Donnell JK, Adler LP, Miraldi F. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997;25:115-9.
  • 18 Vesselle HJ, Miraldi FD. FDG PET of the retroperitoneum: Normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics 1998;18:805-23.
  • 19 Harney JV, Wahl RL, Liebert M, Kuhl DE, Hutchins GD, Wedemeyer G, et al. Uptake of 2-deoxy, 2-( 18 F) fluoro-D- glucose in bladder cancer. Animal localization and initial patient positron emission tomography. J Urol 1991;145:279-83.
  • 20 Drieskens O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:1412-7.
  • 21 Watanabe N, Kato H, Shimizu M, Noguchi K, Kamisaki Y, Fuse H, et al. A case of renal pelvic tumor visualized by 18F- FDG imaging. Ann Nucl Med 2004;18:161-3.
  • 22 Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, et al. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of FDG PET. Q J Nucl Med 2002;46:122-30.
  • 23 Heicappell R, Müller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Müller-Gärtner H, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-( 18 F)-2-deoxy-D-glucose. Eur Urol 1999;36:582-7.
  • 24 Anjos DA, Etchebehere EC, Ramos CD, Santos AO, Albertotti C, Camargo EE. FDG-PET/CT Delayed Images After Diuretic for Restaging Invasive Bladder Cancer. J Nucl Med 2007;48:764-70.
  • 25 Kamel EM, Jichlinski P, Prior JO, Meuwly JY, Delaloye JF, Vaucher L, et al. Forced diuresis improves the diagnostic accuracy of FDG PET in abdominopelvic malignancies. J Nucl Med 2006;47:1803-7.